Stryker Corporation
Recent
price
P/E
ratio
div
yld
1.12%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.
Company News
1,999 Stryker Corporation $SYK Shares Bought by Diversify Advisory Services LLC
PAHC or SYK: Which Is the Better Value Stock Right Now?
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
2 Dividend Stocks to Buy and Hold Forever
Mar Vista U.S. Quality Strategy Q3 2026 Portfolio Review
2 Industries Beyond AI With Long-Term Demand Drivers for 2027
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
The Monopolistic Razor-and-Blade Engine I Can’t Stop Buying
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Stryker (NYSE: SYK) lines up 2027 CEO handoff as Lobo becomes Executive Chair
Stryker announces leadership succession
Stryker: This Dividend Aristocrat Is Finally Cheap Again